Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Source :: PR Newswire. November 25, 2020
Publication Year :: 2020
Abstract: TAIPEI and SAN DIEGO, Nov. 25, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of [...]

Subjects :: United States. Food and Drug Administration
Oncology, Experimental -- Genetic aspects
Tumors -- Drug therapy -- Genetic aspects
Cancer -- Care and treatment -- Research
Business
News, opinion and commentary

Tools